We believe that our technology offers solutions that no one else is able to provide. It's about QUALITY, SPEED, RELIABILITY, and INNOVATION. It's about being able to bring new and life-saving drugs to clinical trials and the patients who need them.
Selexis SUREtechnology Platform™
Redefining best-in-class cell line development technology:
Selexis’ innovation and expertise have enabled the development and ongoing optimization of the most robust and flexible mammalian cell line-based protein expression platform in the industry. The SUREtechnology Platform improves the way that mammalian cells are used in the discovery, development, and manufacturing of any recombinant protein drug. This technology provides several key advantages over traditional approaches: Speed, Productivity, Stability, and Flexibility.
The Selexis team has been able to deploy SUREtechnology to generate nearly 80 clonal research cell banks that have reached clinical and commercial manufacturing, representing one of the industry’s largest portfolios.
Cell line development technologies to help develop and translate new therapies from the lab to the patient
- 250 stable CHO cell pools in 5 weeks for screening campaigns
- High-expressing and stable research cell bank in 14 weeks from transfection
- High and stable expression of recombinant protein therapeutic drug is enabled.
- 1-7 g/L for MAbs (fed-batch culture in shake flask)
- > 90 days stable expression of the recombinant clonal cell lines expressing the therapeutic protein drugs
- Not associated with gene amplifications (such as DHFR/MTX and GS/MSX)
- Not associated with viral transduction or potential future infections
- Enables the expression of any recombinant protein: no more expression bottlenecks (decreased attrition rate)
- Highly effective in several mammalian cells (HEK-293, NS0, CHOs)
The SUREtechnology Platform is fueled by four major components, each of which is supported by a number of proprietary technologies that are unique to Selexis: